Melanoma News and Research

Latest Melanoma News and Research

Patients receiving cancer treatment may experience skin, hair, nail problems

Patients receiving cancer treatment may experience skin, hair, nail problems

EpiCareSRT, Sensus Healthcare aim for mobile non-surgical skin cancer treatment service

EpiCareSRT, Sensus Healthcare aim for mobile non-surgical skin cancer treatment service

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Practice proper sun protection to reduce risk of future skin cancers, warn dermatologists

Practice proper sun protection to reduce risk of future skin cancers, warn dermatologists

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Immune protein exacerbates skin cancer due to sun exposure: Study

Immune protein exacerbates skin cancer due to sun exposure: Study

FDA approves 'Cornell Dots' for first clinical trial in humans to diagnose cancer

FDA approves 'Cornell Dots' for first clinical trial in humans to diagnose cancer

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

King Pharmaceuticals awards payment to Pain Therapeutics for abuse-resistant medications

King Pharmaceuticals awards payment to Pain Therapeutics for abuse-resistant medications

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

FDA accepts Pain Therapeutics NDA resubmission for REMOXY

FDA accepts Pain Therapeutics NDA resubmission for REMOXY

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

New study shows biomarker test can aid in early, precise diagnosis of melanoma

New study shows biomarker test can aid in early, precise diagnosis of melanoma

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.